Lyka Labs Ltd (LYKALABS) — shareholding pattern, promoter holding, financials and share price
About Lyka Labs Ltd (LYKALABS)
Lyka Labs Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as LYKALABS and on the BSE under scrip code 500259. Its ISIN is INE933A01014.
Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages [1]
Lyka Labs Limited is a pharmaceutical company initially focused on formulations and bulk drugs, later expanding into a diverse array of healthcare products.
The company has a broad portfolio including antibiotics, cardiac drugs, anti-inflammatory products, and unique offerings like dextromethorphan hydrobromide lozenges in India.
Listed peers in Pharmaceuticals: BDH Industries Ltd, Astonea Labs Ltd, Zenotech Laboratories Ltd, Aarey Drugs & Pharmaceuticals Ltd, Gennex Laboratories Ltd, Ambalal Sarabhai Enterprises Ltd.
Valuation & Returns
10 Jul 2026At ₹72.36 a share on 10 Jul 2026, Lyka Labs Ltd (LYKALABS) was valued at a price-to-book of 2.82x on a book value of ₹25.68 per share. Solomo computes return on equity of -10.86% and return on capital employed of -6.04% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- Industry P/E
- 36.41x
- P/B
- 2.82x
- EPS (TTM)
- ₹-2.88
- Book value / share
- ₹25.68
- ROE
- -10.86%
- ROCE
- -6.04%
- ROA
- -5.92%
- Debt / equity
- 0.53x
- Dividend yield
- 0%
- EBITDA margin
- -0.12%
- 52-week range
- ₹44.49 – ₹121
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Lyka Labs Ltd (LYKALABS) reported revenue of ₹128 crore, net profit of ₹-10 crore and earnings per share of ₹-2.81. That compares with revenue of ₹138 crore and net profit of ₹8 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹28.03 crore and net profit ₹-8.07 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 194 | 93 | 111 | 138 | 128 |
| Net profit (₹ cr) | 38 | -13 | -3 | 8 | -10 |
| EPS (₹) | 13.59 | -4.3 | -0.75 | 2.24 | -2.81 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 9.25% | 27.02% | -6.42% | 24.56% |
| Profit growth | 6.12% | - | -40.92% | 402.67% |
| Stock price CAGR | 0% | 2% | -14% | -38% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 58.45% of Lyka Labs Ltd (LYKALABS) (up 0.29 pp QoQ), foreign institutional investors (FII) hold 0.17% and domestic institutional investors (DII) hold 0.66%. Market capitalisation was ₹262 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: HUF 2.09%, THERMO CAPITAL PRIVATE LIMITED 1.94%, DALAL & BROACHA STOCK BROKING PVT.LTD. 1.31%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 58.45% | - | 0.17% | 0.66% | 41.55% |
| Mar 2026 | 58.16% | - | 0.29% | 0.67% | 41.84% |
| Dec 2025 | 58.16% | - | 0.17% | 0.67% | 41.84% |
| Sep 2025 | 58.16% | - | 0.18% | 0.67% | 41.84% |
| Jun 2025 | 58.16% | - | 0.16% | 0.67% | 41.84% |
| Mar 2025 | 58.16% | - | 0.23% | 0.67% | 41.84% |
| Dec 2024 | 58.1% | - | 0.15% | 0.67% | 41.9% |
| Sep 2024 | 58.1% | - | 0.15% | 0.67% | 41.9% |